|
1
|
Muñoz Prieto I, Masferrer Pardo J, Olivera
Vegas J, Fortes Alen JR and Pérez Casas AM: Merkel cell carcinoma:
what do we know about it and what should we do? Clin Transl Oncol.
14:401–412. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hughes MP, Hardee ME, Cornelius LA,
Hutchins LF, Becker JC and Gao L: Merkel cell carcinoma:
Epidemiology, target, and therapy. Curr Dermatol Rep. 3:46–53.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koljonen V: Merkel cell carcinoma:
Diagnosis, management, and outcomes. Plast Reconstr Surg.
132:894e–895e. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Becker JC, Kauczok CS, Ugurel S, Eib S,
Bröcker EB and Houben R: Merkel cell carcinoma: Molecular
pathogenesis, clinical features and therapy. J Dtsch Dermatol Ges.
6:709–719. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sharma D, Flora G and Grunberg SM:
Chemotherapy of metastatic Merkel cell carcinoma: case report and
review of the literature. Am J Clin Oncol. 14:166–169. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartholomeusz C and Gonzalez-Angulo AM:
Targeting the PI3K signaling pathway in cancer therapy. Expert Opin
Ther Targets. 16:121–130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hafner C, Houben R, Baeurle A, Ritter C,
Schrama D, Landthaler M and Becker JC: Activation of the PI3K/AKT
pathway in Merkel cell carcinoma. PLoS One. 7:e312552012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nardi V, Song Y, Santamaria-Barria JA, et
al: Activation of PI3K signaling in Merkel cell carcinoma. Clin
Cancer Res. 18:1227–1236. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin Z, McDermott A, Shao L, Kannan A,
Morgan M, Stack BC Jr, Moreno M, Davis DA, Cornelius LA and Gao L:
Chronic mTOR activation promotes cell survival in Merkel cell
carcinoma. Cancer Lett. 344:272–281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kong D and Yamori T: Advances in
development of phosphatidylinositol 3-kinase inhibitors. Curr Med
Chem. 16:2839–2854. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Serra V, Markman B, Scaltriti M, Eichhorn
PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S,
et al: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K
signaling and inhibits the growth of cancer cells with activating
PI3K mutations. Cancer Res. 68:8022–8030. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baumann P, Mandl-Weber S, Oduncu F and
Schmidmaier R: The novel orally bioavailable inhibitor of
phosphoinositol-3-kinase and mammalian target of rapamycin,
NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Exp Cell Res. 315:485–497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cho DC, Cohen MB, Panka DJ, Collins M,
Ghebremichael M, Atkins MB, Signoretti S and Mier JW: The efficacy
of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared
with rapamycin in renal cell carcinoma. Clin Cancer Res.
16:3628–3638. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Erstad DJ and Jr JC: Mutational analysis
of merkel cell carcinoma. Cancers (Basel). 6:2116–2136. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shuda M, Kwun HJ, Feng H, Chang Y and
Moore PS: Human Merkel cell polyomavirus small T antigen is an
oncoprotein targeting the 4E-BP1 translation regulator. J Clin
Invest. 121:3623–3634. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cho DC: Targeting the PI3K/Akt/mTOR
pathway in malignancy: Rationale and clinical outlook. BioDrugs.
28:373–381. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hixon ML, Paccagnella L, Millham R,
Perez-Olle R and Gualberto A: Development of inhibitors of the
IGF-IR/PI3K/Akt/mTOR pathway. Rev Recent Clin Trials. 5:189–208.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Markman B, Dienstmann R and Tabernero J:
Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs. Oncotarget.
1:530–543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hong SW, Shin JS, Moon JH, Kim YS, Lee J,
Choi EK, Ha SH, Lee DH, Chung HN, Kim JE, et al: NVP-BEZ235, a dual
PI3K/mTOR inhibitor, induces cell death through alternate routes in
prostate cancer cells depending on the PTEN genotype. Apoptosis.
19:895–904. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Masuda M, Shimomura M, Kobayashi K, Kojima
S and Nakatsura T: Growth inhibition by NVP-BEZ235, a dual
PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines. Oncol
Rep. 26:1273–1279. 2011.PubMed/NCBI
|
|
21
|
Oishi T, Itamochi H, Kudoh A, Nonaka M,
Kato M, Nishimura M, Oumi N, Sato S, Naniwa J, Sato S, et al: The
PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian
clear cell carcinoma. Oncol Rep. 32:553–558. 2014.PubMed/NCBI
|
|
22
|
Seo BR, Min KJ, Cho IJ, Kim SC and Kwon
TK: Curcumin significantly enhances dual PI3K/Akt and mTOR
inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma
Caki cells through down-regulation of p53-dependent Bcl-2
expression and inhibition of Mcl-1 protein stability. PloS One.
9:e955882014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rosich L, Montraveta A, Xargay-Torrent S,
López-Guerra M, Roldán J, Aymerich M, Salaverria I, Beà S, Campo E,
Pérez-Galán P, et al: Dual PI3K/mTOR inhibition is required to
effectively impair microenvironment survival signals in mantle cell
lymphoma. Oncotarget. 5:6788–6800. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wong J, Welschinger R, Hewson J, Bradstock
KF and Bendall LJ: Efficacy of dual PI-3K and mTOR inhibitors in
vitro and in vivo in acute lymphoblastic leukemia. Oncotarget.
5:10460–10472. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: focus on the PI3K/AKT/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Malumbres M and Barbacid M: Cell cycle
kinases in cancer. Curr Opin Genet Dev. 17:60–65. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Malumbres M, Hunt SL, Sotillo R, Martín J,
Odajima J, Martín A, Dubus P, Ortega S and Barbacid M: Driving the
cell cycle to cancer. Adv Exp Med Biol. 532:1–11. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou BP, Liao Y, Xia W, Spohn B, Lee MH
and Hung MC: Cytoplasmic localization of p21Cip1/WAF1 by
Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat
Cell Biol. 3:245–252. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin
J, Feng GK and Zhu XF: Dual phosphoinositide 3-kinase/mammalian
target of rapamycin inhibitor NVP-BEZ235 has a therapeutic
potential and sensitizes cisplatin in nasopharyngeal carcinoma.
PloS One. 8:e598792013. View Article : Google Scholar : PubMed/NCBI
|
